Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)

NCT00216632 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00216632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2005
Completion date
July 31, 2007
Enrollment
99 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizophrenia